CAM
ALLO icon

ClariVest Asset Management’s Allogene Therapeutics ALLO Stock Holding History

ClariVest Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16,430
Closed -$423K – 749
2021
Q3 		$423K Sell
16,430
-678
-4% -$16.1K 0.01% 451
2021
Q2 		$447K Buy
17,108
+6,784
+66% +$193K 0.01% 442
2021
Q1 		$364K Buy
10,324
+1,701
+20% +$57.4K 0.01% 451
2020
Q4 		$218K Sell
8,623
-11,732
-58% -$382K 0.01% 485
2020
Q3 		$768K Sell
20,355
-952
-4% -$35.9K 0.03% 321
2020
Q2 		$913K Buy
+21,307
New +$771K 0.02% 332

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClariVest Asset Management's ALLO Position: Q4 2021 in Review

ClariVest Asset Management sold out of Allogene Therapeutics (ALLO) in Q4 2021, closing a stake of 16,430 shares — an estimated $423K sold.

ClariVest Asset Management first reported a position in ALLO in Q2 2020 and held it in 6 quarters. The position peaked at $913K in Q2 2020. 177 funds tracked by Wall St. Rank hold ALLO as of Q4 2021.

  • ClariVest Asset Management reported no remaining Allogene Therapeutics position as of Q4 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 16,430 Allogene Therapeutics shares in Q4 2021, an estimated $423K.
  • ClariVest Asset Management first reported a position in Allogene Therapeutics in Q2 2020 and held it in 6 quarters.
  • ClariVest Asset Management's Allogene Therapeutics position peaked at $913K in Q2 2020.
  • 177 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2021.

Based on ClariVest Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.